Objective:To analyze the clinical effect of calcium carbonate D3 combined with recombinant human growth hormone in children with idiopathic short stature.Method:From January 2023 to January 2024,66 children with idiopathic short stature in our hospital were randomly divided into the observation group and the control group(n=33).The control group was treated with subcutaneous injection of recombinant human growth hormone 0.1 IU·kg-1,and the observation group was treated with calcium carbonate D3 orally at 14 mg·kg-1.After continuous treatment for 1 year,height was measured,bone age maturity was evaluated by X-ray examination,and growth factor level was detected by enzyme-linked immunosorbent assay.Results:After treatment,the height,growth rate,and height standard deviation of the observation group were better than those of the control group(P<0.05).The bone age index and bone age difference in the observation group were better than those in the control group(P<0.05).The level of growth factors in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Calcium carbonate D3 combined with recombinant human growth hormone can effectively improve the calcium level,bone maturity,and growth factor levels in children with idiopathic short stature,promoting growth and development.
关键词
特发性矮小症/碳酸钙D3/重组人生长激素/治疗效果
Key words
Idiopathic short stature/Calcium carbonate D3/Recombinant human growth hormone/Treatment effect
维普
万方数据